NCT02002689 - LDE225 for Patients With PTCH1 or SMO Mutated Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

PTCH1 or SMO Activated Solid and Hematologic Tumors

Interventions

DRUG

LDE225

LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule

Trial Locations (10)

Cleveland Clinic Foundation Cleveland Clinic (19), Cleveland

Minnesota Oncology Hematology, P.A. Southdate Medical Center, Minneapolis

Sanford Research Sanford Health, Sioux Falls

Lurie Children's Hospital of Chicago Developmental Therapeutics, Chicago

Oncology Consultants Oncology Group, Houston

MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3), Houston

Intermountain Medical Center Intermountain Healthcare, Murray

University of California Davis Cancer Center UC Davis Cancer (3), Sacramento

Rocky Mountain Cancer Centers RMCC - Aurora, Greenwood Village

Seattle Cancer Care Alliance Skagit Valley Hospital, Seattle